MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Smiths’ H1 sales rise 7 percent
Smiths Group plc (LSE:SMIN) reported pre-tax profits of £224 million ($366.7 million) or 42 pence (69 cents) per basic share, on sales of £1.37 billion ($2.25 billion) during the six months ended Jan. 29. That compares with pre-tax profits of £178 million ($291.4 million), or 35 pence (57 cents) per basic share, on sales of £1.28 billion ($2.09 billion) during the same period last year. (All figures based on current exchange rate of 1USD = .6108GBP)
Read more
Cambridge Heart losses narrow on increased sales
Cambridge Heart Inc. (OTC:CAMH) reported losses of $1.2 million, or 3 cents per diluted share, on sales of $714,620 during the three months ended Dec. 31. That compares with losses of $1.7 million, or 2 cents per diluted share, on revenue of $804,952 during the same period in 2009.
Full-year losses were $5.2 million, or 7 cents per diluted share, on sales of $3.2 million. That compares with losses of $7.3 million, or 12 cents per diluted share, on sales of $2.8 million in 2009.
Read more
Bioject Q4 losses ease on increased sales, but annual sales fall
Bioject Medical Technologies Inc. (OTC:BJCT) reported net losses of $67,000, or less than 1 cent per diluted share, on sales of $1.7 million during the three months ended Dec. 31. That compares with a loss of $395,000, or 2 cents per share, on sales of $1.5 million during the same period in 2009.
Full-year losses were $1.6 million, or 9 cents per diluted share, on sales of $5.6 million. That compares with losses of $1.1 million, or 7 cents per diluted share, on sales of $6.7 million in 2009.
Read more
Instrumentation Laboratory touts record sales
Instrumentation Laboratory reported full-year revenues of €474.2 million ($644.9 million), an 11.5 percent increase versus previous year in current, and 10.3 percent in local currencies.
Read more
Neogen touts 27 percent rise in Q3 profits
Neogen Corp. (NSDQ:NEOG) reported net income of $4.9 million, or 21 cents per diluted share, on revenue of $42.2 million during the three months ended Feb. 28. That compares with a profit of $3.9 million, or 17 cents per diluted share, on revenue of $33.8 million during the same period in 2009.
Read more
Datatrak peeks out of the red
Datatrak International Inc. (OTC:DATA) reported profits of $18,431, or less than 1 cent per diluted share, on sales of $2.0 million during the three months ended Dec. 31. That compares with a loss of $657,274, or 5 cents per diluted share, on sales of $1.5 million during the same period last year.
Full-year profits were $101,109, or 1 cent per diluted share, on revenue of $7.4 million. That compares a loss of $1.9 million, or 14 cents per diluted share, on revenue of $6.9 million in 2009.
Read more
Interleukin losses ease after sales almost double
Interleukin Genetics Inc. (OTC:ILIU) reported losses of $1.2 million, or 3 cents per diluted share, on sales of $510,767 during the three months ended Dec. 31. That compares with losses of $1.8 million, or 6 cents per diluted share, on sales of $185,091 during the same period last year.
Full-year losses were $6.0 million, or 17 cents per diluted share, on revenue of $2.0 million. That compares with losses of $10.6 million, or 33 cents per diluted share, on revenue of $1.1 million in 2009.
Read more
